# Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer

Source: https://onco.cc/trials/nct02170389/  
OnCo record `nct02170389` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

An trial of Rocapuldencel-T run by Roswell Park Cancer Institute, terminated.

## Summary

Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer is an interventional study registered as NCT02170389 by Roswell Park Cancer Institute, with 5 participants enrolled, started 2014-10-14. Conditions recorded: Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer and Stage II Renal Cell Cancer. Interventions recorded: Laboratory Biomarker Analysis, Nephrectomy and Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02170389
- Phase: not-applicable
- Setting: Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
- Sponsor: Roswell Park Cancer Institute
- Enrolled: 5

## Sources

- ClinicalTrials.gov NCT02170389: https://clinicaltrials.gov/study/NCT02170389

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Rocapuldencel-T](https://onco.cc/drugs/rocapuldencel-t/)
- companies: [Argos Therapeutics](https://onco.cc/companies/argos-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct02170389.json